Status: Recruiting
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Participants needed: 91
Trial details
Phase: Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Syncromune, Inc.Updated: Jun 23, 2026Locations: 23
Eligibility criteria
Male >=18 years old. [+21]
Has a known other primary malignancy other than prostate cancer that is progress... [+26]